Conversion Disorder
Conversion disorder is a mental condition in which a person has blindness, paralysis, or other nervous system (neurologic) symptoms that cannot be explained by medical evaluation.
Cluster Number:
Wiki Number: W049
Diagnosis: Conversion Disorder
US Patients: 0.11-0.5%
World Patients:
Sex Ratio: 1M;4W
Age Onset: Ages-10-35
Brain Area: large epinephrine release
Symptoms: psychologically triggered neurological symptoms, numbness, blindness, paralysis or fits,etc.
Progression: Trauma suddenly converted by the brain into physical limitations.
Causes: serious difficulties when no physical basis can be found; usually in motor or sensory systems
Medications:
Therapies: hypnosis, psychotherapy, physical therapy, stress management, transcranial magnetic stimulation; depression may occur.
Youtube Video: A patient’s journey of recovery from
Functional Neurological Disorder at Mass General Hospital
Amazon or Library Book: Out Of My Mind (Conversion Disorder)
Click the book to link or order from Amazon.
Support Group: facebook.com/groups/859712170775277 (Conversion Disorder Group)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.07.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Databy Xingli Xu on March 27, 2025
Background/Objectives: Regadenoson, a selective adenosine A(2A) receptor agonist, is primarily prescribed for myocardial perfusion imaging (MPI). As its clinical use becomes more widespread in practice, assessing its safety in real-world settings is essential. Methods: In this research, disproportionality analysis was applied to evaluate the safety of Regadenoson by examining all adverse event (AE) reports since 2004 in the FDA Adverse Event Reporting System (FAERS), in which Regadenoson was...
- Cortical morphometric similarity gradient in schizophrenia and its association with transcriptional profiles and clinical phenotypeby Yong Han on March 27, 2025
CONCLUSIONS: These findings showed changes in the principal MS network gradient in SCZ and offered potential molecular explanations for the structural changes underpinning SCZ.
- Order-Disorder Transition Induced Dynamic Rashba Effect in 2D Halide Perovskitesby Yang Li on March 26, 2025
Two-dimensional (2D) hybrid organic-inorganic perovskites exhibit pronounced Rashba splitting, positioning them as promising candidates for spintronic applications. However, the underlying mechanism of inversion symmetry breaking and its impact on excitonic optical properties remains elusive. In this study, we investigate a series of 2D Ruddlesden-Popper perovskites and reveal that the order-disorder transition induced by phenyl-based cations triggers a dynamic Rashba effect. At the critical...
- GALM Alleviates Aβ Pathology and Cognitive Deficit Through Increasing ADAM10 Maturation in a Mouse Model of Alzheimer's Diseaseby Na Tian on March 25, 2025
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide, causing dementia and affecting millions of individuals. One prominent characteristic in the brains of AD patients is glucose hypometabolism. In the context of galactose metabolism, intracellular glucose levels are heightened. Galactose mutarotase (GALM) plays a crucial role in maintaining normal galactose metabolism by catalyzing the conversion of β-D-galactose into α-D-galactose (α-D-G). The latter is then...